Pharmafile Logo
Pharmafocus logo
Advanced Search

China

Showing 15 posts of 258 posts found.

CARBOGEN AMCIS manufacturing license advances services in China

April 23, 2025
Manufacturing Services, Manufacturing and Production Carbogen Amcis, China, Corporate, Drug Manufacturing License (DML), Shanghai, manufacturing

Swiss pharma manufacturing company, CARBOGEN AMCIS, has announced that its facility in Shanghai, China, has been successfully granted Drug Manufacturing …

News

NDA in China receives priority review status for lung cancer treatment

January 3, 2025
Research and Development China, China National Medical products Administration, HUTCHMED, NDA, Oncology, epidermal growth factor receptor, non-small cell lung cancer, priority review

HUTCHMED have announced that the China National Medical Products Administration (NMPA) have granted a priority review for a new drug …

News

China’s NMPA accepts Everest Medicines’ Nefecon supplementary application

July 18, 2024
Medical Communications China, Everest Medicines, NMPA, Nephrology

Everest Medicines has announced that China’s National Medical Products Administration (NMPA) has accepted the submission of a supplemental New Drug …

News

AstraZeneca and Sanofi’s Beyfortus approved in China

January 2, 2024
Research and Development AstraZeneca, Beyfortus, China, Immunology, Sanofi

AstraZeneca and Sanofi have announced that Beyfortus (nirsevimab) has been approved in China for the prevention of respiratory syncytial virus …

News

First patient enrolled in Boan Biotech’s phase 3 trial for Nivolumab in China

October 30, 2023
Research and Development Boan Biotech, China, Oncology, clinical trial, nivolumab

Boan Biotech has announced that the first patient has been enrolled in its phase 3 trial of its Nivolumab injection …

News

AstraZeneca’s Calquence approved in China for chronic lymphocytic leukaemia treatment

September 4, 2023
Medical Communications AstraZeneca, CLL, China, Oncology, SLL

AstraZeneca has announced that Calquence (acalabrutinib) has been approved in China for the treatment of adult patients with chronic lymphocytic …

News

AstraZeneca’s Forxiga approved in China for chronic heart failure treatment

August 18, 2023
Medical Communications AstraZeneca, Cardiology, China, cardiovascular, heart failure

AstraZeneca has announced that Forxiga (dapagliflozin) has been approved in China to reduce the risk of cardiovascular death, hospitalisation for …

News

Jacobio Pharma receives CDE approval for pancreatic cancer study in China

July 5, 2023
Medical Communications CDE, China, Jacobio Pharma, Oncology, Pancreatic cancer, clinical trial

Jacobio Pharma has announced that its novel KRAS G12C inhibitor glecirasib’s pivotal study for pancreatic cancer has been approved by …

News
volodymyr-hryshchenko-m1hq4ibp9rc-unsplash

AstraZeneca’s Xigduo XR approved in China for adults with type-2 diabetes

June 27, 2023
Medical Communications AstraZeneca, China, Diabetes, Xigduo XR, diabetes

AstraZeneca has announced that its Xigduo XR (dapagliflozin and metformin hydrochloride extended-release), a once-daily fixed-dose combination, has now been approved …

News

China rejects a second WHO probe into COVID outbreak origin

July 22, 2021
COVID-19, China

China has rejected WHO plans for a second investigation into the origin of the coronavirus pandemic, which includes the hypothesis …

News

Positive phase III results achieved for dialysis drug in China

April 30, 2021
Medical Communications China, Kideny disease

Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced positive results from a phase-III study in China (PA-CL-CHINA-01), evaluating the …

News
3500

UAE rolls out Sinopharm COVID-19 vaccine amid conflicting reports of efficacy

December 15, 2020
Manufacturing and Production, Research and Development COVID-19, China, Sinopharm, UAE, coronavirus

The United Arab Emirates has begun rolling out Sinopharm’s COVID-19 vaccine in its capital Abu Dhabi, despite claims that numerous …

News
takeda_usa_pharmaceuticals_u

China approves Takeda’s Takhzyro to prevent hereditary angioedema attacks in patients over 12

December 8, 2020
Manufacturing and Production, Sales and Marketing China, Takeda

China’s National Medical Products Administration (NMPA) has given approval in the country for Takeda’s Takhzyro (lanadelumab), in a subcutaneous injection …

News

China approves Astellas’ Xtandi in non-metastatic castration-resistant prostate cancer

November 6, 2020
Medical Communications, Sales and Marketing Astellas, China, NMPA, Xtandi

China’s drug regulator, the National Medical Products Administration (NMPA), has given the green light to Astellas to market Xtandi (enzalutamide …

News
steve_bannon_32289717844

Study that alleges COVID-19 was made in a Chinese lab originated from non-profits linked to ex-Trump advisor Steve Bannon

September 16, 2020
Research and Development China, Donald Trump, Steve Bannon, Wuhan, coronavirus

A new study that alleges COVID-19 was created in a Chinese lab was published by two non-profits that are linked …

News
The Gateway to Local Adoption Series

Latest content

Historic UN declaration supporting mental health – treatment to be given similar priority to chronic diseases

January 30, 2026

Rare diseases – spinal muscular atrophy

January 30, 2026

Could targeting the molecular causes of infertility finally transform IVF success rates?

January 29, 2026

Digital mental health technologies – a valuable tool in supporting people with depression and anxiety

January 29, 2026

Barts Health NHS Trust collaborates with H.I.G. Realty on healthcare innovation building

January 29, 2026